The prevalence of HPV infections in HPV-vaccinated women from the general population

APMIS. 2017 Jun;125(6):585-595. doi: 10.1111/apm.12677. Epub 2017 Mar 15.

Abstract

Currently, three prophylactic HPV vaccines are commercially available to prevent HPV 16/18 infection and associated lesions. The aim of the study was to assess markers of HPV infection in women/girls before vaccination and to ascertain the prevalence and spectrum of post-vaccination HPV types. Three hundred and thirty subjects of which 75 were virgins were enrolled. Before the first dose of the HPV vaccine and 1, 3 and 5 years after the completion of HPV vaccination, the samples for cytology, HPV detection and anti-HPV antibody response were taken. At enrolment, HPV DNA was detected in 38% of sexually active girls/women. At the first, second and third follow-up, HPV DNA was found in 40, 45, and 39% of them. The seroprevalence rates to HPV 6, 11, 16 and 18 in these subjects were 31, 21, 18 and 10%. On the follow-up significantly higher levels of antibodies to HPV 16/18 were found after application of divalent vaccine. Results of the study demonstrate high prevalence of HPV infection in young women. In a substantial number of women, HPV-specific antibodies as well as high-risk HPV types were detected. HPV-specific antibodies were also frequently found in non-sexually active girls. The acquisition of HPV after the onset of sexual life was very fast.

Keywords: DNA; HPV; antibodies; infection; persistence; vaccination.

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Viral / blood*
  • Cervix Uteri / pathology
  • Cervix Uteri / virology
  • Cohort Studies
  • DNA, Viral / analysis
  • Female
  • Humans
  • Middle Aged
  • Papillomaviridae / isolation & purification
  • Papillomavirus Infections / epidemiology*
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Vaccines / administration & dosage
  • Papillomavirus Vaccines / immunology*
  • Seroepidemiologic Studies
  • Young Adult

Substances

  • Antibodies, Viral
  • DNA, Viral
  • Papillomavirus Vaccines